CD274 and non-small cell lung carcinoma: A previous clinical study demonstrated that ipilimumab was efficacious in enhancing the therapeutic response when administered in conjunction with PD-L1 antibody in patients with advanced renal cell carcinoma, melanoma, and non-small cell lung cancer [32,33].